Syndax

Reimagining Cancer Treatment

Second Quarter 2026 Financial Results and Business Update

August 4, 2026

Forward-looking statements disclosure

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events, progress, timing or circumstances) are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding future operations, financial results and the financial condition of Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company"), including financial position, strategy and plans, the progress, timing, clinical development and scope of clinical trials and the reporting of clinical data for Syndax's product candidates, the progress of regulatory submissions and approvals and subsequent commercialization and the potential use of Syndax's product candidates to treat various cancer indications and fibrotic diseases, and Syndax's expectations for liquidity and future operations, are forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical studies or clinical trials, clinical site activation rates or clinical trial enrollment rates that are lower than expected; changes in expected or existing competition; the impact of macroeconomic conditions (the Russia-Ukraine war, inflation, among others) on Syndax's business and that of the third parties on which Syndax depends, including delaying or otherwise disrupting Syndax's clinical trials and preclinical studies, manufacturing and supply chain, or impairing employee productivity; failure of our collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Moreover, Syndax operates in a very competitive and rapidly changing environment. Other factors that may cause our actual results to differ from current expectations are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. New risks emerge from time to time. It is not possible for Syndax's management to predict all risks, nor can Syndax assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied. Except as required by law, neither Syndax nor any other person assumes responsibility for the accuracy and completeness of the forward- looking statements. Syndax undertakes no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in Syndax's expectations.

Strong 2Q26 results with multiple drivers for sustainable growth

ROBUST 2Q26 COMMERCIAL DEMAND

- **$55M in Revuforj net revenue** (+91% y/y), highlighting leadership in menin inhibition, robust demand in NPM1 and KMT2A, and an increasing average duration of therapy
- **$60M in Niktimvo net revenue** (+67% y/y), resulting in $18M in collaboration revenue
- **$73M in total revenue to Syndax** (+92% y/y)

EXCELLENT PIPELINE PROGRESS

- Advanced leadership in menin inhibition; **positioned to be 1st to frontline (1L) AML**
- On track for **Ph 2 axatilimab data in IPF and 1L cGVHD in 4Q26**
- Announced **two new pipeline assets with first- and best-in-class potential** in EGFRm NSCLC and myelofibrosis

SOLID FINANCIAL FOUNDATION

- **$575M in cash** and equivalents; fully funded to advance strategic priorities
- **Driving towards profitability** with growing product revenues and strong patent protection into at least late 2030s[1]

Syndax

1. Patent protection into at least late 2030s for Revuforj and Niktimvo and at least 2040s for SNDX-4321 and SNDX-62122.
y/y, year-over-year; IPF, idiopathic pulmonary fibrosis; cGVHD, chronic graft-versus-host disease; EGFRm NSCLC, EGFR-mutated non-small cell lung cancer

Strong 2Q26 Revuforj results with sixth consecutive quarter of double-digit net revenue and prescription growth

2Q26 Revuforj results

$54.7M
net revenue

91% growth vs. 2Q25
12% growth vs. 1Q26

~1,500
total prescriptions

~121% growth vs. 2Q25
~15% growth vs. 1Q26

2Q growth reflects an increasing average treatment duration, primarily driven by a growing pool of patients on Tx post-HSCT

>30%
of 2Q26 net revenue from NPM1 business

~1,630
patients treated commercially since launch



TRx, total prescriptions; HSCT, hematopoietic stem cell transplant; Tx, treatment

Strong fundamentals in place to drive Revuforj growth

NEW PATIENT STARTS  **X** **TREATMENT DURATION**  **=** **MARKET OPPORTUNITY**

- Opportunity to address **~6.5K R/R patients annually:**
  - **~2K patients with R/R KMT2A-translocated** acute leukemia
  - **~4.5K patients with R/R NPM1-mutated** AML
- Only FDA approved menin inhibitor for R/R KMT2A patients
- Leader in R/R NPM1m with room for further growth

- **Increasing average treatment duration** driven by evolving clinical practice
- Used in **early lines of R/R treatment and in combinations:**
  - ~75% of use in 2L/3L
  - ~40% of use in combination
- **~50% of KMT2A patients proceed to HSCT and ~50% have resumed Tx thus far**

- Comprehensive clinical development program underway targeting **$5B+ U.S. TAM across R/R and frontline acute leukemia**

Revuforj is positioned for success with an outstanding commercial foundation

Broad and expanding prescriber base

88%

of Tier 1+2 accounts activated

>580

total accounts (+11% q/q growth)

Excellent payer coverage with no meaningful barriers to access

98%

of all covered lives with formulary coverage for both Revuforj indications

Syndax

All covered lives includes all commercially covered lives plus Medicare and Medicaid lives.

Strong Niktimvo 2Q26 results driven by robust demand

$60.3M

2Q26 net revenue to INCY

67% growth vs. 2Q25

9% growth vs. 1Q26

$18.1M

2Q26 collaboration revenue to SNDX

93% growth vs. 2Q25

13% growth vs. 1Q26

>300

2Q26 new patients

~5,750

2Q26 infusions administered

Performance reflects strong, consistent new patient starts and solid persistency

Syndax records 50% of the Niktimvo net commercial profit, defined as net revenue (recorded by Incyte) minus the cost of sales and commercial expenses.

Niktimvo is positioned for continued growth and success in cGVHD

Strong Adoption in 4L with Growing Use in 3L cGVHD

Approx. one-third of 3L+ cGVHD market within 1.5 years of launch

Extended Tx Durations to Address Chronic Disease

~60-70% of patients stay on therapy for at least 12 months

Broad Prescriber Base

Nearly every U.S. BMT center has ordered and become a repeat customer

Strong Commercial Synergies

Niktimvo targets overlap with key accounts where Syndax and Incyte have deep relationships

3L, third line; 4L, fourth line; BMT, bone marrow transplant centers; Tx, treatment

Recent medical meetings and publications highlight Syndax's scientific leadership in menin inhibition

June	June	June	July
ASCO	eha	Journal of Clinical Oncology® An American Society of Clinical Oncology Journal	Cancer Cell
Presented 4 revumenib abstracts, including an oral presentation of post-HSCT maintenance data	Presented 12 revumenib abstracts spanning multiple acute leukemia settings and subtypes	Published first data for an all-oral, menin-based combo in R/R NPM1m, KMT2Ar, & NUP98r AML	Published landmark preclinical data showing potential for menin inhibition in MPNs
			

Additional 1L, maintenance, real-world, and R/R revumenib data anticipated in 2H26 + beyond

A ROBUST AND GROWING PIPELINE OF PROGRAMS

Positioned to be the 1st to deliver pivotal 1L data for a menin inhibitor

Phase 2 axatilimab data in IPF and 1L cGVHD anticipated in 4Q26

At least 4 innovative assets expected in the clinic in 2027



R/R, relapsed or refractory; 1L, frontline; AML, acute myeloid leukemia; SOC, standard of care; MRD, measurable residual disease; cGVHD, chronic graft-versus-host disease; rux, ruxolitinib; IPF, idiopathic pulmonary fibrosis; NSCLC, non-small cell lung cancer. *Trials led by Incyte.

Expanding our pipeline to fuel the next phase of innovation and growth

SNDX-4321

Mutant-selective, CNS-penetrant, allosteric EGFR inhibitor for NSCLC



- Novel approach to addressing patients with L858R mutations, CNS metastases, atypical activating mutations, or acquired resistance to current drugs
- **Allosteric approach allows for:**
  - ✓ **SNDX-4321 and ATP-site directed drugs (e.g., Tagrisso) to bind EGFR at the same time** ('double drugging' may enhance efficacy and delay resistance)
  - ✓ **High selectivity** (supports tolerability and combinability)
- **IND submission expected by YE26**; demonstration of monotherapy activity anticipated early 2028

SNDX-62122

Next-generation menin inhibitor for myelofibrosis (MF)



- Novel, **potentially disease-modifying mechanism in MF**
- **1st candidate from our internally developed, wholly owned library of next-gen menin inhibitors**
- Profile:
  - ✓ Higher potency, increased selectivity, optimized PK, and activity against common resistance mutations
- **IND submission + Ph 1 initiation expected in 2027**, building on proof-of-principle trial of revumenib in MF

Strong financial position with growing revenue and a robust balance sheet

Financial Summary *($ in millions)*	Three Months Ended June 30	
	2026	2025
Product revenue, net (Revuforj)	54.7	28.6
Collaboration revenue, net (Niktimvo)	18.1	9.4
Total revenues	**72.8**	**38.0**
Cost of product sales	(3.2)	(1.3)
Research & development (R&D)	(68.0)	(62.2)
Selling, general and administrative (SG&A)	(41.5)	(43.8)
Total operating expenses	**(112.8)**	**(107.3)**
Other (expense) income, net	(9.4)	(2.5)
Net loss	**(49.4)**	**(71.8)**

On the road to profitability

AS OF 30 JUN 2026:

$575.1M
in cash and equivalents[1]

89.4M
shares outstanding[2]

2026 R&D + SG&A EXPENSE GUIDANCE:

$400M, excluding $50M in expected stock option expense

Syndax

Totals may not sum due to rounding; 1. Includes short- and long-term investments; 2. Includes pre-funded warrants to purchase 285,714 common shares (rounded).

WELL POSITIONED FOR LONG-TERM GROWTH WITH MULTIPLE BLOCKBUSTER OPPORTUNITIES AND UPCOMING MILESTONES

Revuforj® (revumenib) tablets
25 mg • 110 mg • 160 mg

Positioned to be 1st menin approved in 1L AML; peak annual net revenue in excess of $2B expected in the U.S. alone

Niktimvo™ (axatilimab-csfr)

Phase 2 readouts in IPF and 1L cGVHD in 4Q26 target new multi-billion-dollar opportunities



Mutant-selective, allosteric EGFR inhibitor



Next-generation menin inhibitor

Two pipeline assets with best-in-class and blockbuster potential in EGFRm NSCLC and myelofibrosis

$575M
in cash and equivalents

Funded through profitability with capital to drive innovation and long-term value creation

Multiple near-term catalysts and blockbuster opportunities

Anticipated milestones

Revuforj (revumenib) & SNDX-62122	**Acute Leukemia** • Advance global enrollment in pivotal 1L trials of revumenib • New 1L, maintenance, real-world, and R/R revumenib data in 2H26 + beyond • Publish R/R NUP98r data in 4Q26 **Myelofibrosis** • Initiate Ph 1/2 proof-of-principle trial with revumenib in 4Q26; initial data 2H27 • Submit IND and initiate Ph 1 SNDX-62122 trial in 2027
Niktimvo (axatilimab-csfr)	**Chronic GVHD** • Ph 2 axatilimab + ruxolitinib data in 4Q26 • Ph 3 axatilimab + corticosteroid data early 2028 **Idiopathic pulmonary fibrosis** • Ph 2 MAXPIRe data in 4Q26
SNDX-4321	**EGFRm NSCLC** • Submit IND by YE 2026 • Initiate Ph 1 trial in 2027; initial data early 2028

FUELED BY A PASSION FOR PATIENTS

Syndax

Sarah, diagnosed with R/R acute leukemia